NRX Pharmaceuticals (NRXP) Other Non-Current Assets (2020 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Other Non-Current Assets of $276000.0 for Q1 2026, down 17.37% year-over-year from $334000.0 in Q1 2025, and up 9.09% quarter-over-quarter from $253000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Other Non-Current Assets (2020 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Other Non-Current Assets for 7 consecutive years, with $276000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 17.37% year-over-year to $276000.0; the TTM figure through Mar 2026 stood at $276000.0 (down 17.37% YoY), while the FY2025 annual figure was $253000.0, down 25.37% from the prior year.
- Other Non-Current Assets advanced to $276000.0 in Q1 2026 per NRXP's latest filing, from $253000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $441000.0 in Q1 2024 and bottomed at $17000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $203000.0 across 5 years, with a median of $248000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 1952.38% — and 2025, when it slumped 35.42%.
- NRX Pharmaceuticals' Other Non-Current Assets stood at $21000.0 in 2022, then jumped by 1952.38% to $431000.0 in 2023, then fell by 21.35% to $339000.0 in 2024, then retreated by 25.37% to $253000.0 in 2025, then increased by 9.09% to $276000.0 in 2026.
- Business Quant data shows NRXP's Other Non-Current Assets at $276000.0 in Q1 2026, $253000.0 in Q4 2025, and $243000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 224,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 276,000.00 |
| Dec 31, 2025 | 253,000.00 |
| Sep 30, 2025 | 243,000.00 |
| Jun 30, 2025 | 248,000.00 |
| Mar 31, 2025 | 334,000.00 |
| Dec 31, 2024 | 339,000.00 |
| Sep 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 441,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 24,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 17,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 15,921.00 |
| Jun 30, 2021 | 12,730.00 |